|
Kidney Diseases
|
0.090 |
Biomarker
|
group |
BEFREE |
In conclusion, GLP-1 RAs are safe regarding nephropathy- and retinopathy-related outcomes.
|
30058208 |
2019 |
|
Kidney Diseases
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Both GLP1-RA (HR, 0.82; 95% CI, 0.75-0.89; P<0.001) and SGLT2i (HR, 0.62; 95% CI, 0.58-0.67; P<0.001) reduced the risk of progression of kidney disease including macroalbuminuria, but only SGLT2i reduced the risk of worsening estimated glomerular filtration rate, end-stage kidney disease, or renal death (HR, 0.55; 95% CI, 0.48-0.64; P<0.001).
|
30786725 |
2019 |
|
Kidney Diseases
|
0.090 |
Biomarker
|
group |
BEFREE |
In conclusion, the results of the present study indicated that GLP‑1 may be a promising target for the development of novel therapeutic strategies for HG‑induced nephropathy, and may function through the activation of SIRT1.
|
29845208 |
2018 |
|
Kidney Diseases
|
0.090 |
Biomarker
|
group |
BEFREE |
Although previous studies have reported the protective effect of glucagon-like peptide-1 (GLP-1) in diabetes nephropathy, the molecular mechanism such as nephroprotection remains elusive.
|
29526117 |
2018 |
|
Kidney Diseases
|
0.090 |
Biomarker
|
group |
BEFREE |
GLP1-RA appear to reduce the incidence and/or progression of nephropathy and to have no specific effect on retinopathy-with the notable exception of semaglutide, which could have a negative impact on the retina.
|
28748377 |
2017 |
|
Kidney Diseases
|
0.090 |
GeneticVariation
|
group |
BEFREE |
42 cases of patients with DN admitted in our hospital from April 2010-May 2015 were selected and divided into phase I-II group (group A, n = 22) and phase III-IV group (group B, n = 20) according to DN phases and 20 cases of patients with diabetes rather than nephropathy admitted in our hospital during the same period were selected as the control group, all of whom underwent the routine biochemical test and gastrointestinal hormone test, the differences in gastrin (GAS), motilin (MTL) and glucagon (GLC) of DN patients were compared at different phases, the gastric emptying test was carried out on them and the gastric emptying time was recorded.
|
28829486 |
2017 |
|
Kidney Diseases
|
0.090 |
Biomarker
|
group |
BEFREE |
These benefits may be consistent with the known effects of GLP-1 RA on traditional risk factors for progressive kidney disease including glucose lowering, blood pressure lowering, reduced insulin levels and weight reduction.
|
28431667 |
2017 |
|
Kidney Diseases
|
0.090 |
AlteredExpression
|
group |
BEFREE |
GLP-1 plasma levels were determined in 3 different patient cohorts: 1) critically ill patients admitted to our intensive care unit (n = 215); 2) patients with chronic kidney disease on hemodialysis (n = 173); and 3) a control group (no kidney disease, no acute inflammation, n = 105).
|
28366423 |
2017 |
|
Kidney Diseases
|
0.090 |
Biomarker
|
group |
BEFREE |
GLP-1 agonists did not affect the risk of MI (RR: 0.917; CI: 0.830-1.014; p = 0.092) as well as the risk of stroke (RR: 0.882; CI: 0.759-1.023; p = 0.097), HF (RR: 0.967; CI: 0.803-1.165; p = 0.725), retinopathy (RR: 1.000; CI: 0.807-1.238; p = 0.997) and nephropathy (RR: 0.866; CI: 0.625-1.199; p = 0.385).
|
29113708 |
2017 |